Regeneron Supplies 500 Inmazeb® Doses To WHO For Low-Income Nations To Fight Ebola Outbreaks

Regeneron Pharmaceuticals, Inc.,  announced it will donate up to 500 doses of its Ebola treatment, Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn), to the World Health Organization (WHO). The donation is designated for governments in low- and lower-middle-income countries, ensuring continued free access to this critical therapy for populations most at risk of Ebola outbreaks.

The initiative complements Regeneron’s existing stockpile delivery to the U.S. Department of Health and Human Services (HHS) as part of national emergency preparedness efforts. Additionally, Regeneron is expediting shipments of Inmazeb to the Democratic Republic of the Congo (DRC), where a new outbreak is underway. Since 2018, Regeneron has partnered with public health agencies and NGOs to provide Inmazeb at no cost under compassionate use protocols in outbreak regions, including the DRC and Guinea. By June 2025, 266 patients had received the therapy.

“Ebola is a notoriously dangerous and highly contagious disease, with a fatality rate of up to 90 percent when untreated. During the 2018 outbreak, Regeneron changed the world’s approach to Ebola by applying our innovative VelociSuite® technology and rapid response protocols to develop Inmazeb, the first FDA-approved treatment for this deadly disease. Our donation advances our corporate responsibility goal of breaking down barriers to patient access and will benefit the most vulnerable people. We thank the world-class scientists, government and public health leaders, and courageous healthcare providers whose collaboration made this possible,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. 

Inmazeb is FDA-approved for treating infections caused by Orthoebolavirus zairense (Zaire ebolavirus) in adults and pediatric patients, including newborns exposed in utero. The therapy, developed using Regeneron’s VelocImmune® and VelociSuite® platforms, combines three monoclonal antibodies that block the virus from entering host cells while also engaging the immune system to clear infected cells.